Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 4/20 | 0.40 |
| ▸ | MAOA | P21397 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | NQO1 | P15559 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1304737 | 0.78 | ESR2 (0.43) | ALDH1A1CYP3A4CYP2C9CYP2C19MAOB | |
| SCHEMBL209082 | 0.72 | ALDH1A1 (0.34) | ALDH1A1CYP3A4MAOBKDM4ESMN1; SMN2 | |
| SCHEMBL466442 | 0.72 | MAOB (0.47) | ALDH1A1CYP3A4MAOBMAOAKDM4E | |
| SCHEMBL932337 | 0.69 | MAOA (0.59) | ALDH1A1CYP3A4MAOBMAOAKDM4E | |
| SCHEMBL208818 | 0.68 | CYP1A2 (0.33) | ALDH1A1CYP3A4MAOBKDM4ESMN1; SMN2 | |
| SCHEMBL5013425 | 0.68 | ALDH1A1 (0.58) | ALDH1A1CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL1611070 | 0.66 | ALPG (0.59) | ALDH1A1CYP3A4KDM4ESMN1; SMN2NPC1 | |
| SCHEMBL12646917 | 0.66 | NQO1 (0.47) | ALDH1A1CYP3A4MAOBKDM4ESMN1; SMN2 | |
| SCHEMBL4454971 | 0.66 | ALDH1A1 (0.47) | ALDH1A1CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL9056199 | 0.66 | ALDH1A1 (0.55) | ALDH1A1CYP3A4CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2091945-B1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2014-01-15 | — | — | EP | claimed |
| US-11931412-B2 | JAK1 inhibitors and uses thereof | WASHINGTON UNIVERSITY (US) | 2024-03-19 | — | — | US | disclosed |
| US-20210338812-A1 | JAK1 INHIBITORS AND USES THEREOF | WASHINGTON UNIVERSITY (US) | 2021-11-04 | — | — | US | disclosed |
| US-10973913-B2 | JAK inhibitors and uses thereof | WASHINGTON UNIVERSITY (US) | 2021-04-13 | — | — | US | disclosed |
| US-20200282051-A1 | JAK INHIBITORS AND USES THEREOF | WASHINGTON UNIVERSITY (US) | 2020-09-10 | — | — | US | disclosed |
| EP-2344158-B1 | USE OF ISOQC INHIBITORS | PROBIODRUG AG (DE) | 2017-12-27 | — | — | EP | disclosed |
| WO-2017143014-A1 | JAK INHIBITORS AND USES THEREOF | KIM BRIAN (US) | 2017-08-24 | — | — | WO | disclosed |
| US-9656991-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2017-05-23 | — | — | US | disclosed |
| US-9650362-B2 | Inhibitors | PROBIODRUG AG (DE) | 2017-05-16 | — | — | US | disclosed |
| EP-2865670-B1 | Thiourea derivatives as glutaminyl cyclase inhibitors | PROBIODRUG AG (DE) | 2017-01-11 | — | — | EP | disclosed |
| US-20080267912-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-10-30 | — | — | US | disclosed |
| WO-2008128981-A1 | NITROVINYL-DIAMINE DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008128983-A1 | CYANO-GUANIDINE DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008128985-A1 | THIOUREA DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008128987-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2008-10-30 | — | — | WO | disclosed |
| US-20080262063-A1 | Compounds of formula (I), combinations and uses thereof for disease therapy,** Image-1or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein: | PROBIODRUG AG (DE) | 2008-10-23 | — | — | US | disclosed |
| US-20080262065-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASES | PROBIODRUG AG (DE) | 2008-10-23 | — | — | US | disclosed |
| US-20080221086-A1 | Novel Inhibitors of Glutaminyl Cyclase | PROBIODRUG AG (DE) | 2008-09-11 | — | — | US | disclosed |
| WO-2008055945-A1 | 3-HYDR0XY-1,5-DIHYDR0-PYRR0L-2-ONE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE FOR THE TREATMENT OF ULCER, CANCER AND OTHER DISEASES | PROBIODRUG AG (DE) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008055947-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338812-A1 | JAK1 INHIBITORS AND USES THEREOF | JAK1, JAK2, JAK3 | ALDH1A1 1074/4885CYP3A4 3004/4885CYP2D6 3550/4885 |
| US-20080262065-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASES | GLS, GLS2, GLUL | ALDH1A1 1467/4885CYP3A4 2962/4885CYP2D6 3089/4885 |
| US-20080221086-A1 | Novel Inhibitors of Glutaminyl Cyclase | GLS, GLS2, GLUL | ALDH1A1 1395/4885CYP3A4 2214/4885CYP2D6 1479/4885 |
| US-10973913-B2 | JAK inhibitors and uses thereof | JAK2, JAK1, JAK3 | ALDH1A1 2806/4885CYP3A4 2865/4885CYP2D6 3043/4885 |
| US-11931412-B2 | JAK1 inhibitors and uses thereof | JAK1, JAK3, JAK2 | ALDH1A1 1366/4885CYP3A4 3800/4885CYP2D6 4159/4885 |
| US-20080267912-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | GLS, GLS2, QPCT | ALDH1A1 1847/4885CYP3A4 2767/4885CYP2D6 2890/4885 |
| US-20080262063-A1 | Compounds of formula (I), combinations and uses thereof for disease therapy,** Image-1or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein: | MAPT, SLC10A1, REN | ALDH1A1 547/4885CYP3A4 207/4885CYP2D6 431/4885 |
| US-20200282051-A1 | JAK INHIBITORS AND USES THEREOF | JAK2, JAK1, JAK3 | ALDH1A1 2806/4885CYP3A4 2865/4885CYP2D6 3043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.